Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Jason L. J. Dearling"'
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Background A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an
Externí odkaz:
https://doaj.org/article/6402ece3f46c433b8dd6fe849ec705f0
Autor:
R.D. Seidel, Ross W. Cheloha, Ella L. Zeyang, Stephen C. Kolifrath, Alan B. Packard, Rodolfo J. Chaparro, Mohammad Rashidian, Steven C. Almo, Scott J. Garforth, Jason L. J. Dearling, Stad H. Zeigler, Phaneendra K. Duddempudi, Andrew W. Woodham, Hidde L. Ploegh, Maia Mesyngier
Publikováno v:
Nature methods
The immune system’s ability to recognize peptides on major histocompatibility molecules (pMHCs) contributes to eradication of cancers and pathogens. Tracking these responses in vivo could help evaluate the efficacy of immune interventions and impro
Autor:
Rajesh Kumar, Julia Garcia Mancebo, Ryan Patenaude, Kristen Sack, Maksymilian Prondzynski, Alan B. Packard, Jason L. J. Dearling, Ruihan Li, Michelle Balcarcel‐Monzon, Saffron Dominguez, Sirisha Emani, John N. Kheir, Brian Polizzotti, Yifeng Peng
Publikováno v:
Advanced Materials. 34:2207376
Colloids, known as volume expanders, have been used as resuscitation fluids for hypovolemic shock for decades, as they increase plasma oncotic pressure and expand intravascular volume. However, recent studies show that commonly used synthetic colloid
Autor:
Amy L. Vāvere, Scott E. Snyder, Armita Bahrami, Jitendra K. Mishra, Yuanyuan Han, Jason L. J. Dearling, Victor Amador Diaz, Alan B. Packard, Shana V. Stoddard, Heather Tillman, Jieun Kim, Elizabeth R. Butch, Paul E. Mead, Elizabeth Stewart, Barry L. Shulkin
Publikováno v:
Cancer Research. 79:3112-3124
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on 99%, P < 0.05). These res
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-14 (2021)
EJNMMI Research
EJNMMI Research
Background A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an attracti
Detection and Description of Tissue Disease: Advances in the Use of Nanomedicine for Medical Imaging
Autor:
Alan B. Packard, Jason L. J. Dearling
Publikováno v:
Handbook of Harnessing Biomaterials in Nanomedicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f06274d8e4b0686ac040158fc447fa0
https://doi.org/10.1201/9781003125259-9
https://doi.org/10.1201/9781003125259-9
Autor:
Alan B. Packard, Niels Dammes, Nuphar Veiga, Meir Goldsmith, Jason L. J. Dearling, Srinivas Ramishetti, Dan Peer
Publikováno v:
Nature Nanotechnology
Nature nanotechnology
Nature nanotechnology
The successful in vivo implementation of gene expression modulation strategies relies on effective, non-immunogenic delivery vehicles. Lipid nanoparticles are one of the most advanced non-viral clinically approved nucleic-acid delivery systems. Yet l
Autor:
Alan B. Packard, Jason L. J. Dearling
Publikováno v:
Journal of Controlled Release. 261:23-30
The development of nanomedicines presents the potential to deliver more potent drugs targeted more specifically to the site(s) of disease than is currently achievable. While encouraging results have been achieved, including at the clinical level, sig
Autor:
Alan B. Packard, Jason L. J. Dearling
Publikováno v:
Current Radiopharmaceuticals. 10:59-64
Background: Measurement of trace metal contamination is critical in the production of radiometals, such as 64Cu, for protein labeling. ICP-MS provides these data with high sensitivity and high specificity, but at high (instrument) cost. TETA (1,4,8,1
Publikováno v:
Inflammatory Bowel Diseases. 22:529-538
BACKGROUND Positron emission tomography combined with a specific probe presents the ability to noninvasively assess inflammatory bowel disease. We previously reported increased intestinal uptake of a Cu-labeled anti-β7 integrin antibody (clone FIB50